Akebia Therapeutics, Inc..
AKBA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with kidney disease. The company's lead product candidate is vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which is being...Show More
Better Health for All
20
Akebia Therapeutics' lead product, Vafseo® (vadadustat), is intended for the treatment of anemia due to chronic kidney disease (CKD).
1
However, its prescribing information includes a BOXED WARNING detailing potential risks such as death, myocardial infarction (MI), stroke, venous thromboembolism, thrombosis of vascular access, hepatotoxicity, hypertension, seizures, and gastrointestinal erosion.
2
The company demonstrates strong efforts in patient access, with Vafseo qualifying for Transitional Drug Add-On Payment Adjustment (TDAPA) reimbursement.
3
The AkebiaCares program for Auryxia® (ferric citrate) offers copay assistance, allowing eligible commercially insured patients to pay as little as $0
4
, provides free medication for uninsured and Medicare Part D patients with dialysis
5
, and offers Low-Income Subsidy (LIS) assistance for those with incomes at or below 150% of the federal poverty level.
6
Eligibility for AkebiaCares extends to household incomes below 600% of the Federal Poverty Level.
7
Commercial supply contracts for Vafseo cover nearly 100% of dialysis patients in the U.S.
8
Risk transparency is demonstrated through the Full Prescribing Information for Vafseo, which includes a BOXED WARNING and Medication Guide.
9
Fair Money & Economic Opportunity
0
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease. The provided articles describe patient assistance and copay programs for their medication, AURYXIA, which offer discounts on medication costs. These programs, such as the Auryxia® Copay Card providing up to $1,500 per 30-day supply, are not considered financial services, lending, or deposit activities as defined by the 'Fair Money & Economic Opportunity' value.
1
As the company does not offer financial products or services to consumers, all Key Performance Indicators related to this value are not applicable.
Fair Pay & Worker Respect
20
For the 2024 fiscal year, Akebia Therapeutics reported a CEO-to-median-employee pay ratio of 17:1.
1
CEO John P. Butler's total compensation was $4,260,114, and the median employee pay was $248,328.
2
The company offers a comprehensive benefits package that includes health, dental, and vision insurance.
3
Akebia states it is an equal opportunity employer.
4
No regulatory actions, violations, or fines related to labor laws or human rights are mentioned in the provided articles. The company has also issued a recruitment fraud notice, advising that legitimate recruiting correspondence comes from an @akebia.com email address and does not involve any fees for job seekers.
5
Fair Trade & Ethical Sourcing
0
The provided articles do not contain any information regarding Akebia Therapeutics, Inc.'s fair trade or ethical sourcing practices.
1
,
2
There is no evidence related to fair-trade certifications, supplier audit frequency, incidents of forced or child labor, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, spend on high-risk materials, or supplier diversity initiatives.
3
,
4
Honest & Fair Business
0
The provided articles do not contain specific information regarding regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict of interest percentages, anti-corruption policies, or third-party verification of ethical claims. While Akebia Therapeutics, Inc. has SEC filings and annual reports available
1
, these documents do not provide the quantitative or qualitative data required to assess the company against the specified KPIs for Honest & Fair Business.
Kind to Animals
0
The provided articles do not contain specific information regarding Akebia Therapeutics, Inc.'s policies, practices, or performance related to animal welfare. There is no evidence on cruelty-free certifications, alternative testing usage, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits for welfare, cage-free sourcing, animal testing policy or volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement on animal welfare. Mentions of regulatory pushes to eliminate animal testing are general industry observations, not specific to Akebia's actions or policies.
1
No War, No Weapons
-40
Akebia Therapeutics received funding from the Department of Defense for a Phase II clinical trial of its drug Vadadustat.
1
The company reported a net negative impact score of -0.53 for 'Equality & Human Rights', calculated from a positive impact of +0.03 and a negative impact of -0.56.
2
Planet-Friendly Business
-70
Akebia Therapeutics, Inc. has no reported data on its total Scope 1, 2, and 3 greenhouse gas emissions
1
. The company has not declared a net-zero target year
2
and lacks reported science-based carbon reduction targets or climate pledges
3
. However, no regulatory actions, violations, fines, or compliance issues related to environmental matters have been mentioned for the company
4
.
Respect for Cultures & Communities
0
No information regarding Akebia Therapeutics, Inc.'s engagement with cultures and communities, formal partnerships, community investment, cultural impact assessments, or any related metrics was found in the provided article.
1
Safe & Smart Tech
0
Akebia Therapeutics has no documented data breaches or reported incidents of unauthorized user data use.
1
The company conducts security training for all new personnel and embedded contractors on compliance issues, including its Code of Business Conduct and Ethics, and launched training in 2024 focused on equal opportunity and bias mitigation for all employees.
2
However, no metrics on training effectiveness or completion rates are provided. Encryption and authentication security are integrated into systems, and vulnerability management processes and annual security tests and incident simulations are in place, but specific details on their extent, strength, or effectiveness are not disclosed.
3
The company has a Privacy Policy effective August 2023
4
and provides contact information for privacy inquiries, including specific channels for California residents.
5
The company demonstrates good regulatory compliance, with a Regulation FD Policy amended on June 10, 2025, to meet SEC requirements.
6
It declares compliance with California Health & Safety Code Sections 119400-119402, effective June 30, 2025
7
, and aligns its policies with the PhRMA Code on Interactions with Healthcare Professionals.
8
Its Comprehensive Compliance Program is based on the OIG Guidance for Pharmaceutical Manufacturers
9
, and the Audit Committee oversees the healthcare compliance program.
10
Zero Waste & Sustainable Products
0
No specific data on waste management, sustainability, or zero-waste practices was found in the provided articles
1
. This includes information on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education
2
.